Frontage Holdings Corporation FGHQF

Company Overview

Frontage Holdings Corporation is a contract research organization (CRO) focused on providing integrated, science-driven drug discovery and development services to pharmaceutical, biotechnology, and agrochemical companies. The company operates across the preclinical and clinical development value chain, supporting customers with laboratory testing, bioanalytical services, chemistry, manufacturing and controls (CMC), early-stage drug discovery, and clinical trial support. Frontage primarily serves biotechnology and pharmaceutical companies developing small molecules, biologics, and cell and gene therapies, with operations concentrated in the United States and China.

The company’s principal revenue drivers include laboratory testing services, bioanalytical and DMPK (drug metabolism and pharmacokinetics) studies, central laboratory services, and manufacturing support for investigational products. Frontage has positioned itself as a cross-border CRO capable of supporting both U.S. and Chinese regulatory and development requirements, which has historically differentiated it from smaller regional competitors. The company traces its origins to Frontage Laboratories, founded in the United States in 2001, and later expanded through acquisitions and investments into China-based operations. Frontage Holdings Corporation became publicly listed on the Hong Kong Stock Exchange in 2018.